Capricor Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€11.47M - Cost of goods sold
€589.28K - Gross profit
€10.83M - SG&A expenses
€16.36M - R&D expenses
€57.64M - EBITDA
-€60.33M - D&A
€977.93K - EBIT
-€62.85M - Interest expenses
€0.00 - EBT
-€59.91M - Tax expenses
€0.00 - Net income
-€59.91M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€6.63B - Changes in working capital
€69.54K - Operating cash flow
-€28.14M - Capex
€1.66M - Other investing cash flow
€65.81B - Net investing cash flow
€6.07B - Total cash dividends paid
€0.00 - Issuance of common stock
€126.74M - Debt repayment
€0.00 - Other financing cash flow
€146.69K - Net financing cash flow
€127.10M - Foreign exchange effects
€0.00 - Net change in cash
€15.50M - Cash at end of period
€0.00 - Free cash flow
-€26.49M
Balance sheet
- Cash and cash equivalents
€19.90M - Cash and short-term investments
€105.13M - Total receivables
€50.95K - Inventory
€0.00 - Other current assets
€1.08M - Total current assets
€106.26M - Property, plant & equipment
€7.65M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€434.90K - Total non-current assets
€8.08M - Total assets
€114.35M - Accounts payable
€4.12M - Short-term debt
€3.62M - Other current liabilities
€6.30M - Total current liabilities
€24.31M - Long-term debt
€166.76M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€166.60K - Total liabilities
€24.48M - Common stock
€39.13K - Retained earnings
-€214.14M - Other equity
€1.19M - Total equity
€89.87M - Total liabilities and shareholders' equity
€114.35M
Company information
- Market capitalization
€434.70M - Employees
160 - Enterprise Value
€573.06M
Company ratios
- Gross margin
-
94.5% Much better than peer group: -1,501,191,844,855.5% - EBITDA margin
-
-526.2% Much better than peer group: -4,868,440,978,513.2% - EBIT margin
-
-548.1% Much better than peer group: -5,018,199,300,938.1% - EBT margin
-
-522.5% Much better than peer group: -4,878,879,040,299.5% - Net margin
-
-522.5% Much better than peer group: -4,878,879,003,229.8% - ROE
-
-66.7% Much better than peer group: -385.5% - ROA
-
-52.4% Much better than peer group: -287.6% - Asset turnover
-
10.0% Worse than peer group: 27.8% - FCF margin
-
-259.9% Much better than peer group: -4,468,353,450,664.3% - FCF yield
-6.9% - Efficiency ratio
626.2% - Net sales per employee
-
€71.66K - Net income per employee
-
-€374.42K